Browse Illinois Research and Scholarship (Open Collection) by Subject "genetics"

  • Zettler, Patricia J.; Sherkow, Jacob S.; Greely, Henry T. (JAMA Internal Medicine, 2014-03-01)
    On November 22, 2013, the US Food and Drug Administration (FDA) effectively halted health-related direct-to-consumer genetic testing in the United States by sending a warning letter to 23andMe, the leading company in the ...

    application/pdf

    application/pdfPDF (51kB)
  • Sherkow, Jacob S.; Abbott, Ryan (British Medical Bulletin, 2018-03-28)
    Physicians have long worried about gene patents’ potential to restrict their medical practices. Fortune and hindsight have proven these worries exaggerated both in the UK and elsewhere. Neither current nor future medical ...

    application/pdf

    application/pdfPDF (217kB)
  • Sherkow, Jacob S.; Greely, Henry T. (Annual Review of Genetics, 2015-12-04)
    The US Supreme Court’s recent decision in Association for Molecular Pathology v. Myriad Genetics, Inc. declared, for the first time, that isolated human genes cannot be patented. Many have wondered how genes were ever the ...

    application/pdf

    application/pdfPDF (336kB)
  • Sherkow, Jacob S. (Nature Biotechnology, 2015-03-06)
    Predicting the outcome of the ongoing patent disputes surrounding genome-editing technology is equal parts patent analysis and history. Genome-editing technology based on clustered, regularly interspaced, short palindromic ...

    application/pdf

    application/pdfPDF (129kB)
  • Sherkow, Jacob S.; Scott, Christopher Thomas (Nature Biotechnology, 2014-07-08)
    Myriad took no prisoners on its way to the top of the molecular diagnostics field. That strategy is unlikely to endure.

    application/pdf

    application/pdfPDF (139kB)
  • Sherkow, Jacob S. (Milbank Quarterly, 2019-07-10)
    The 2013 decision by the Supreme Court of the United States in Association for Molecular Pathology v. Myriad Genetics, Inc. was seen by many as a triumph for public health. The opinion declared human genes to be ineligible ...

    application/pdf

    application/pdfPDF (88kB)
  • Sherkow, Jacob S. (Oxford University Press, 2017-12-07)
    The revolutionary gene-editing technology, CRISPR, has raised numerous ethical, legal, and social concerns over its use. The technology is also subject to an increasing patent thicket that raises similar issues concerning ...

    application/pdf

    application/pdfPDF (340kB)
  • Contreras, Jorge L.; Sherkow, Jacob S. (Science, 2017-03-24)
    In response to a letter from Lawrence Horn, MPEG LA, suggesting patent pools for CRISPR licensing, we respond that while patent pools have been successfully deployed in the consumer electronics and other markets, we question ...

    application/pdf

    application/pdfPDF (682kB)
  • Sherkow, Jacob S. (Biochemist, 2016-06-01)
    New gene-editing technologies, like CRISPR, promise revolutionary advances in biology and medicine. However, several patent disputes in the USA and UK may have complicated who can use CRISPR. What does this mean for the ...

    application/pdf

    application/pdfPDF (299kB)